199 related articles for article (PubMed ID: 17237270)
1. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
Anai S; Goodison S; Shiverick K; Hirao Y; Brown BD; Rosser CJ
Mol Cancer Ther; 2007 Jan; 6(1):101-11. PubMed ID: 17237270
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.
Anai S; Shiverick K; Medrano T; Nakamura K; Goodison S; Brown BD; Rosser CJ
Urology; 2007 Oct; 70(4):832-7. PubMed ID: 17991582
[TBL] [Abstract][Full Text] [Related]
3. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
5. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
Xu L; Yang D; Wang S; Tang W; Liu M; Davis M; Chen J; Rae JM; Lawrence T; Lippman ME
Mol Cancer Ther; 2005 Feb; 4(2):197-205. PubMed ID: 15713891
[TBL] [Abstract][Full Text] [Related]
6. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
7. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
Loriot Y; Mordant P; Brown BD; Bourhis J; Soria JC; Deutsch E
Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
[TBL] [Abstract][Full Text] [Related]
9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
10. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts.
Anai S; Goodison S; Shiverick K; Iczkowski K; Tanaka M; Rosser CJ
Hum Gene Ther; 2006 Oct; 17(10):975-84. PubMed ID: 16984224
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
[TBL] [Abstract][Full Text] [Related]
12. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
Cao W; Yacoub S; Shiverick KT; Namiki K; Sakai Y; Porvasnik S; Urbanek C; Rosser CJ
Prostate; 2008 Aug; 68(11):1223-31. PubMed ID: 18465755
[TBL] [Abstract][Full Text] [Related]
13. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
[TBL] [Abstract][Full Text] [Related]
15. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
Anai S; Brown BD; Nakamura K; Goodison S; Hirao Y; Rosser CJ
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1161-8. PubMed ID: 17637391
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
Jiang H; Xia D; Wu LJ; Chen ZD
Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Dandekar DS; Lokeshwar BL
Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
20. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]